Cipla, India's third-largest drugmaker by revenue, reported a weaker-than-expected fourth-quarter profit on Wednesday, dragged by weak sales amid stiff competition in its key US market.
The drugmaker's consolidated net profit fell 54.6 per cent year-on-year to ₹555 crore ($58 million) in the quarter ended March 31, missing analysts' average estimate of ₹705 crore, according to data compiled by LSEG.
Published on May 13, 2026
THIS AD SUPPORTS OUR JOURNALISM.
SUBSCRIBE
FOR MINIMAL ADS.
THIS AD SUPPORTS OUR JOURNALISM.
SUBSCRIBE
FOR MINIMAL ADS.
